Company Overview and News
New Zealand shares dropped after Fonterra Cooperative Group cut its dividend forecast, weighing on the Fonterra Shareholders' Fund and A2 Milk Co. Steel & Tube Holdings plunged to a 17-year low after warning of a full-year loss.
New Zealand shares fell today, led by a poor day of trading for Comvita and A2 Milk.
New Zealand shares rose, led by A2 Milk Co and Synlait Milk while Pushpay fell after annual earnings met its guidance, disappointing some upbeat investors.
A volatile price for A2 Milk saw New Zealand shares fall today, with the S&P NZX 50 index down 153 points (1.76%) to 8555, on turnover of $254 million.
New Zealand shares fell as A2 Milk Co disappointed investors with a market update, dragging down partner Synlait Milk.
New Zealand shares rose ahead of the MSCI rebalancing tomorrow, with possible addition A2 Milk leading gains while Fletcher Building and Mercury New Zealand, rumoured to be leaving, dropped.
New Zealand shares fell slightly, despite a gain in energy stocks and ANZ Bank New Zealand rising on its first-half earnings.
New Zealand shares rallied across the board, with Mercury New Zealand and Kiwi Property Group leading the index while Scales Corp and Comvita dropped.
New Zealand shares dipped with Westpac Banking Corp and Australia & New Zealand Banking Group down as the banking scandal across the Tasman deepens, while Tegel Group surged on a planned takeover offer.
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.
New Zealand shares fell, led by Pushpay Holdings after the mobile app payments developer posted its first dip in quarterly revenue, while blue-chip stocks a2 Milk Co, Fletcher Building and Fisher & Paykel Healthcare declined. Infratil gained on upbeat earnings guidance.
New Zealand shares rose as the local bourse joined a region-wide rally on optimism the US and China will manage to avoid a trade war that could slow global growth. Sky Network Television, Fisher & Paykel Healthcare and Spark NZ led broad-based gains. Orion Health jumped 11 per cent.
New Zealand shares gained, led by Sky Network Television bouncing back and Orion Health surging 20 per cent after it confirmed it's considering sale options.
New Zealand shares fell, led by Sky Network Television, Genesis Energy and Fletcher Building while Kathmandu Holdings and Synlait Milk gained.
New Zealand shares fell on the last day of the quarter, led lower by A2 Milk Co on continued selling from increased competition and further weakening from Fletcher Building.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...